Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HTT | P42858 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10696444 | 0.76 | MTNR1A (0.38) | NPSR1KMT2AMEN1ALDH1A1HTT | |
| SCHEMBL6929485 | 0.73 | CA12 (0.47) | KMT2AMEN1CYP3A4ALDH1A1HTT | |
| SCHEMBL11145996 | 0.72 | NPSR1 (0.42) | NPSR1KMT2AMEN1SMN1; SMN2CYP3A4 | |
| SCHEMBL11845758 | 0.71 | ESR1 (0.41) | NPSR1KMT2AMEN1HSP90AA1HTT | |
| SCHEMBL3809800 | 0.71 | ALDH1A1 (0.46) | NPSR1KMT2AMEN1SMN1; SMN2CYP3A4 | |
| SCHEMBL3054163 | 0.70 | KDM4E (0.39) | NPSR1KMT2AMEN1SMN1; SMN2HSP90AA1 | |
| SCHEMBL124582 | 0.70 | NPSR1 (0.46) | NPSR1KMT2AMEN1SMN1; SMN2CYP3A4 | |
| SCHEMBL9743711 | 0.70 | NPSR1 (0.46) | NPSR1KMT2AMEN1SMN1; SMN2CYP3A4 | |
| SCHEMBL3915161 | 0.70 | MEN1 (0.44) | NPSR1KMT2AMEN1SMN1; SMN2CYP3A4 | |
| SCHEMBL9214815 | 0.70 | TSHR (0.53) | KMT2AMEN1CYP3A4ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104520309-B | N- substitution second generation derivatives of antifungal antibiotic amphotericin B and its preparation method and application | 布里特股份公司 | 2018-05-04 | — | — | CN | claimed |
| EP-0018546-B1 | PROCESS FOR THE PRODUCTION OF PHENYLGLYCYL CHLORIDE HYDROCHLORIDES | BIOCHEMIE Gesellschaft m.b.H. (AT) | 1983-09-28 | — | — | EP | claimed |
| EP-0018546-A2 | Process for the production of phenylglycyl chloride hydrochlorides | BIOCHEMIE Gesellschaft m.b.H. (AT) | 1980-11-12 | — | — | EP | claimed |
| CN-106061947-B | Cyclohexyl sulfone ROR gamma modulators | 百时美施贵宝公司 | 2019-12-03 | — | — | CN | disclosed |
| CN-110520423-A | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO | 2019-11-29 | — | — | CN | disclosed |
| CN-110214137-A | As αvThe indazole derivative of integrin antagonists | 百时美施贵宝公司 | 2019-09-06 | — | — | CN | disclosed |
| CN-110191887-A | The Imidazopyridazine regulator of IL-12, IL-23 and/or IFN-α | 百时美施贵宝公司 | 2019-08-30 | — | — | CN | disclosed |
| CN-110167934-A | Monocycle and spiro-compound containing cyclobutane and containing azetidine as α V integrin inhibitor | 百时美施贵宝公司 | 2019-08-23 | — | — | CN | disclosed |
| CN-110167933-A | Azole amides and amines as α V integrin inhibitors | 百时美施贵宝公司 | 2019-08-23 | — | — | CN | disclosed |
| CN-110139864-A | pyrrole amides as α V integrin inhibitors | 百时美施贵宝公司 | 2019-08-16 | — | — | CN | disclosed |
| CN-110036015-A | It can be used as the Imidazopyridazine compounds of the regulator of IL-12, IL-23 and/or IFN α response | 百时美施贵宝公司 | 2019-07-19 | — | — | CN | disclosed |
| US-20100009404-A1 | PRODUCTION OF BETA-LACTAM ANTIBIOTICS | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2010-01-14 | — | — | US | disclosed |
| EP-2084270-A2 | PRODUCTION OF BETA-LACTAM ANTIBIOTICS | DSMIP Assets B.V. (NL) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008040731-A3 | PRODUCTION OF BETA-LACTAM ANTIBIOTICS | DSM IP ASSETS BV (NL) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008040731-A2 | PRODUCTION OF BETA-LACTAM ANTIBIOTICS | DSM IP ASSETS B.V. (NL) | 2008-04-10 | — | — | WO | disclosed |
| US-20050124029-A1 | Process for the preparation of a betha- lactam antibiotic with mutated penicillin acylase | DSM IP ASSESTS B.V. (NL) | 2005-06-09 | — | — | US | disclosed |
| WO-2004111241-A1 | PENICILLIN ACYLASE | STICHTING VOOR DE TECHNISCHE WETENSCHAPPEN (NL) | 2004-12-23 | — | — | WO | disclosed |
| EP-1456370-A2 | PROCESS FOR THE PREPARATION OF A BETA-LACTAM ANTIBIOTIC WITH MUTATED PENICILLIN ACYLASE | DSM IP Assets B.V. (NL) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003055998-A2 | PROCESS FOR THE PREPARATION OF A BETA-LACTAM ANTIBIOTIC WITH MUTATED PENICILLIN ACYLASE | DSM IP ASSETS B.V. (NL) | 2003-07-10 | — | — | WO | disclosed |
| US-4619925-A | ANTIBIOTICS FOR GRAMPOSITIVE AND GRAMNEGATIVE BACTERIA | BRISTOL-MYERS COMPANY (US) | 1986-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124029-A1 | Process for the preparation of a betha- lactam antibiotic with mutated penicillin acylase | BET1, COASY, PGGT1B | NPSR1 4332/4885KMT2A 703/4885MEN1 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.